Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 101
interventional 75
Observational 24
Registry 2

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 30
Drug|placebo 11
Device 8
Procedure 6
Drug|Other 4
Other 3
Combination Product|Procedure 2
Radiation 2
Behavioral|Procedure 1
Biological 1
Biological|Device|Procedure 1
Biological|Procedure 1
Combination Product 1
Device|Drug 1
Dietary Supplement 1
Drug|Procedure 1
placebo 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 27
France 9
Brazil 6
NA 5
Canada 4
United Kingdom 3
Denmark 2
Germany 2
Israel 2
United States|Australia 2
Austria 1
Denmark|Norway|Sweden 1
Finland 1
France|Switzerland 1
Italy 1
Netherlands 1
Russian Federation 1
Turkey 1
United States|Australia|Belgium|Germany|India|Israel|Italy|Norway|Poland|Spain|Tunisia|United Kingdom 1
United States|Australia|Belgium|Germany|India|Poland|Spain 1
United States|Australia|France|United Kingdom 1
United States|Australia|Germany 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 57
2 4
3 3
4 2
5 1
6 1
11 2
13 1
15 1
22 1
23 1
27 1

Phase

Phase Study_Count
Phase 2 25
N/A 18
Phase 3 13
Phase 1 9
Phase 4 7
Phase 1/Phase 2 2
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 23
2 36
3 2
4 2
5 1
NA 11

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.3 Phase.4
Min. 10 3.0000 1.00000 18 5.00 23.00000 19.00000
1st Qu. 10 9.7500 5.00000 18 14.00 30.00000 23.50000
Median 10 27.0000 7.00000 18 30.00 46.00000 30.00000
Mean 10 202.6667 10.44444 18 39.52 69.69231 40.14286
3rd Qu. 10 51.5000 10.00000 18 58.00 112.00000 35.00000
Max. 10 2174.0000 42.00000 18 159.00 180.00000 115.00000

Trial Group Type

group_type Group_Count
Experimental 56
Active Comparator 24
Placebo Comparator 14
Other 12
NA 11
Sham Comparator 5
No Intervention 3

Intervention Model

intervention_model Study_Count
Single Group Assignment 35
Parallel Assignment 31
Crossover Assignment 7
NA 2

Primary Purpose

primary_purpose Study_Count
Treatment 68
Diagnostic 2
Supportive Care 2
Basic Science 1
Other 1
Prevention 1

Observational Studies

Studies by Country

Country Study_Count
NA 6
United Kingdom 5
United States 5
Germany 3
France 2
Israel 1
United States|Canada|Netherlands 1
United States|India|Israel|Italy 1

Sites per Study

Site_count Study_Count
1 22
5 1
16 1

Enrollment Metrics

Measure Observational
Min 8.000
1st Qu 60.000
Median 100.000
Mean 1144.762
3rd Qu 207.000
Max 20000.000

Observation Model

observational_model Study_Count
Cohort 11
NA 8
Other 3
Case-Control 1
Family-Based 1

Time Perspective

time_perspective Study_Count
Prospective 12
NA 5
Retrospective 4
Cross-Sectional 2
Other 1

Registries

Studies by Country

Country Study_Count
Canada 1
United States|Australia 1

Sites per Study

Site_count Study_Count
1 1
2 1

Enrollment Metrics

Measure Registries
Min 1000
1st Qu 5750
Median 10500
Mean 10500
3rd Qu 15250
Max 20000

Registry Model

observational_model Study_Count
Case-Only 1
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 2

Follow-up

target_duration Study_Count
10 Years 1
100 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03397004 Doxycycline for Hereditary Hemorrhagic Telangiectasia https://ClinicalTrials.gov/show/NCT03397004 Recruiting St. Michael’s Hospital, Toronto 2020-12-31
NCT03321916 MacTel Laser Study https://ClinicalTrials.gov/show/NCT03321916 Recruiting The Lowy Medical Research Institute Limited 2020-12-31
NCT03319849 A Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2 https://ClinicalTrials.gov/show/NCT03319849 Recruiting Neurotech Pharmaceuticals 2022-03-31
NCT03316300 A Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2 https://ClinicalTrials.gov/show/NCT03316300 Recruiting Neurotech Pharmaceuticals 2022-03-31
NCT03071965 Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel) https://ClinicalTrials.gov/show/NCT03071965 Enrolling by invitation Neurotech Pharmaceuticals 2021-04-15
NCT02977637 MRA With Feraheme in HHT https://ClinicalTrials.gov/show/NCT02977637 Completed University of California, Los Angeles 2018-11-30
NCT02770807 EDS in Ataxia Telangiectasia Patients https://ClinicalTrials.gov/show/NCT02770807 Recruiting Erydel 2020-11-30
NCT02761174 Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias https://ClinicalTrials.gov/show/NCT02761174 Completed Bispebjerg Hospital 2016-07-11
NCT02754479 A Clinical Evaluation of the Treatment of Spider Veins on the Ankles https://ClinicalTrials.gov/show/NCT02754479 Completed Cutera Inc. 2017-03-31
NCT02733679 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone https://ClinicalTrials.gov/show/NCT02733679 Completed NHS Tayside 2017-08-30
NCT02657252 Polidocanol Versus Glucose Treatment of Telangiectasia Trial https://ClinicalTrials.gov/show/NCT02657252 Completed UPECLIN HC FM Botucatu Unesp 2016-09-30
NCT02484716 Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO) https://ClinicalTrials.gov/show/NCT02484716 Completed Hospices Civils de Lyon 2017-11-30
NCT02464644 Frequency of Common Medical Conditions in People With and Without HHT https://ClinicalTrials.gov/show/NCT02464644 Completed Imperial College London 2015-05-31
NCT02389959 Intranasal Bevacizumab for HHT-Related Epistaxis https://ClinicalTrials.gov/show/NCT02389959 Recruiting Stanford University 2019-09-30
NCT02345200 Body Composition and Hormonal Status in Ataxia Telangiectasia https://ClinicalTrials.gov/show/NCT02345200 Completed Johann Wolfgang Goethe University Hospital 2014-04-30
NCT02345135 Susceptibility to Infections in Ataxia Telangiectasia https://ClinicalTrials.gov/show/NCT02345135 Completed Johann Wolfgang Goethe University Hospital 2016-01-31
NCT02287558 Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study https://ClinicalTrials.gov/show/NCT02287558 Recruiting The Cleveland Clinic 2019-06-30
NCT02104271 Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial. https://ClinicalTrials.gov/show/NCT02104271 Completed Barretos Cancer Hospital 2014-12-31
NCT01314274 Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) https://ClinicalTrials.gov/show/NCT01314274 Completed Medical University of Vienna 2013-06-30
NCT03152019 Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT) https://ClinicalTrials.gov/show/NCT03152019 Completed Hospices Civils de Lyon 2018-11-08
NCT04113187 Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients https://ClinicalTrials.gov/show/NCT04113187 Recruiting University Hospital, Bordeaux 2022-06-30
NCT01975103 Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases https://ClinicalTrials.gov/show/NCT01975103 Recruiting Federal University of Rio Grande do Sul 2020-04-30
NCT01949324 A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel https://ClinicalTrials.gov/show/NCT01949324 Completed Neurotech Pharmaceuticals 2017-04-14
NCT01752049 Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept https://ClinicalTrials.gov/show/NCT01752049 Completed St. Michael’s Hospital, Toronto 2019-08-30
NCT01507480 The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia https://ClinicalTrials.gov/show/NCT01507480 Completed Hospices Civils de Lyon 2012-12-31
NCT01491620 Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte https://ClinicalTrials.gov/show/NCT01491620 Completed Cutera Inc. 2013-05-31
NCT01485224 Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia https://ClinicalTrials.gov/show/NCT01485224 Completed IRCCS Policlinico S. Matteo 2014-10-31
NCT01408732 Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia https://ClinicalTrials.gov/show/NCT01408732 Completed University of Minnesota 2014-09-30
NCT01408030 North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) https://ClinicalTrials.gov/show/NCT01408030 Completed Augusta University 2014-09-30
NCT01402531 Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) https://ClinicalTrials.gov/show/NCT01402531 Completed University of California, San Diego 2013-07-27
NCT01397695 Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) https://ClinicalTrials.gov/show/NCT01397695 Completed University of California, San Diego 2014-01-31
NCT01362192 Treatment of Lower Extremity Spider Veins With Excel V https://ClinicalTrials.gov/show/NCT01362192 Completed Cutera Inc. 2011-11-30
NCT01327911 Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel) https://ClinicalTrials.gov/show/NCT01327911 Completed Neurotech Pharmaceuticals 2016-09-30
NCT04336163 Skin Imaging to Inform Laser Treatments https://ClinicalTrials.gov/show/NCT04336163 Recruiting University of California, Irvine 2020-12-31
NCT04274842 D-OCT of Facial Telangiectasia Treated With IPL https://ClinicalTrials.gov/show/NCT04274842 Completed Zealand University Hospital 2018-10-01
NCT04148950 Effects of Kinesio Taping Method on Functional Capacity and Quality of Life in Patients With Chronic Venous Disease https://ClinicalTrials.gov/show/NCT04148950 Completed Istanbul University 2015-05-31
NCT04139018 Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia https://ClinicalTrials.gov/show/NCT04139018 Recruiting Washington University School of Medicine 2020-10-20
NCT04132323 Low Concentrate Detergents Versus Hypertonic Glucose for the Treatment of Telangiectasia https://ClinicalTrials.gov/show/NCT04132323 Recruiting Derzhavin Tambov State University 2020-07-15
NCT04108052 Diagnostic Value of Ultra-low Dose Thoracic Scanner for the Pulmonary Arteriovenous Malformation Detection in HHT Patient https://ClinicalTrials.gov/show/NCT04108052 Recruiting Hospices Civils de Lyon 2020-11-30
NCT04004728 Laser Treatment Of Leg Telangiectasias https://ClinicalTrials.gov/show/NCT04004728 Completed University of Sao Paulo 2011-08-31
NCT03981562 Vitamin D and Hereditary Haemorrhagic Telangiectasia https://ClinicalTrials.gov/show/NCT03981562 Recruiting St. Paul’s Hospital, Canada 2020-07-01
NCT03962114 Effects of Vitamin B3 in Patients With Ataxia Telangiectasia https://ClinicalTrials.gov/show/NCT03962114 Enrolling by invitation Radboud University 2019-12-01
NCT03940690 Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease https://ClinicalTrials.gov/show/NCT03940690 Recruiting Fondation Ophtalmologique Adolphe de Rothschild 2022-11-30
NCT03910244 Pomalidomide for the Treatment of Bleeding in HHT https://ClinicalTrials.gov/show/NCT03910244 Recruiting The Cleveland Clinic 2022-03-31
NCT03759678 N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T) https://ClinicalTrials.gov/show/NCT03759678 Recruiting IntraBio Inc 2020-07-01
NCT03669393 A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1) https://ClinicalTrials.gov/show/NCT03669393 Recruiting Oxurion 2019-12-31
NCT03646955 Partial Breast Versus no Irradiation for Women With Early Breast Cancer https://ClinicalTrials.gov/show/NCT03646955 Recruiting Danish Breast Cancer Cooperative Group 2033-09-01
NCT03563053 Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study https://ClinicalTrials.gov/show/NCT03563053 Recruiting Erydel 2020-08-31
NCT03472859 Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser https://ClinicalTrials.gov/show/NCT03472859 Completed Tampere University Hospital 2018-06-09
NCT01205035 High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia https://ClinicalTrials.gov/show/NCT01205035 Completed Eye Center of Northern Colorado, P.C. 2012-10-31
NCT01031992 Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) https://ClinicalTrials.gov/show/NCT01031992 Completed University Hospital, Saarland 2002-08-31
NCT00950196 Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia https://ClinicalTrials.gov/show/NCT00950196 Completed Sheba Medical Center 2009-11-30
NCT00843440 Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study https://ClinicalTrials.gov/show/NCT00843440 Completed Hospices Civils de Lyon 2009-03-31
NCT02638012 Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT) https://ClinicalTrials.gov/show/NCT02638012 Completed St. Michael’s Hospital, Toronto 2019-10-31
NCT03845049 Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1 https://ClinicalTrials.gov/show/NCT03845049 Recruiting Centre Hospitalier Universitaire Dijon 2022-01-31
NCT03227263 BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). https://ClinicalTrials.gov/show/NCT03227263 Completed Hospices Civils de Lyon 2020-05-15
NCT02286804 Ultherapy for the Treatment of Spider Veins on the Legs https://ClinicalTrials.gov/show/NCT02286804 Completed Merz North America, Inc. 2015-04-30
NCT00725244 Trial of Endoscopy Bipolar and Argon of Chronic Rectal Bleeding From Radiation Telangiectasias https://ClinicalTrials.gov/show/NCT00725244 Completed Federal University of São Paulo 2007-11-30
NCT00685854 Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth https://ClinicalTrials.gov/show/NCT00685854 Completed National Institutes of Health Clinical Center (CC) 2011-03-24
NCT00685503 Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth https://ClinicalTrials.gov/show/NCT00685503 Completed National Institutes of Health Clinical Center (CC) 2011-04-12
NCT00656409 Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) https://ClinicalTrials.gov/show/NCT00656409 Completed Institute of Child Health NA
NCT00640003 Baclofen Treatment of Ataxia Telangiectasia https://ClinicalTrials.gov/show/NCT00640003 Completed Johns Hopkins University 2011-02-28
NCT00504400 Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial) https://ClinicalTrials.gov/show/NCT00504400 Completed University Hospital, Bonn 2009-06-30
NCT00470977 Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy https://ClinicalTrials.gov/show/NCT00470977 Completed Manhattan Eye, Ear & Throat Hospital 2010-12-31
NCT00457145 Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation https://ClinicalTrials.gov/show/NCT00457145 Completed National Institutes of Health Clinical Center (CC) NA
NCT00457067 Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation https://ClinicalTrials.gov/show/NCT00457067 Completed National Institutes of Health Clinical Center (CC) NA
NCT00451763 Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia https://ClinicalTrials.gov/show/NCT00451763 Completed University of Sao Paulo 2006-12-31
NCT00389935 Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding https://ClinicalTrials.gov/show/NCT00389935 Completed Northport Veterans Affairs Medical Center 2011-06-30
NCT00378196 Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial https://ClinicalTrials.gov/show/NCT00378196 Completed Johns Hopkins University 2007-09-30
NCT00375622 Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial https://ClinicalTrials.gov/show/NCT00375622 Completed Rabin Medical Center NA
NCT00355108 ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome https://ClinicalTrials.gov/show/NCT00355108 Completed Hospices Civils de Lyon 2010-05-31
NCT00211328 Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.). https://ClinicalTrials.gov/show/NCT00211328 Completed Manhattan Eye, Ear & Throat Hospital NA
NCT00187057 Study for Treatment of Cancer in Children With Ataxia-telangiectasia https://ClinicalTrials.gov/show/NCT00187057 Completed St. Jude Children’s Research Hospital 2006-08-31
NCT00004654 Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia https://ClinicalTrials.gov/show/NCT00004654 Completed Office of Rare Diseases (ORD) NA
NCT00004327 Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia https://ClinicalTrials.gov/show/NCT00004327 Completed Office of Rare Diseases (ORD) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT02983253 Immunmodulation in Patients With HHT https://ClinicalTrials.gov/show/NCT02983253 Completed University Hospital, Essen 2019-10-31
NCT02936349 Graded TTCE for Post-Embolization PAVM Monitoring https://ClinicalTrials.gov/show/NCT02936349 Completed University of Pennsylvania 2019-11-30
NCT01942850 International Ataxia Rating Scale in Younger Patients https://ClinicalTrials.gov/show/NCT01942850 Completed Erydel 2014-05-31
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions https://ClinicalTrials.gov/show/NCT01931644 Recruiting Sanguine Biosciences 2025-08-31
NCT01803516 QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser https://ClinicalTrials.gov/show/NCT01803516 Completed Memorial Sloan Kettering Cancer Center 2018-02-28
NCT01590121 Hereditary Haemorrhagic Telangiectasia Flight Safety Study https://ClinicalTrials.gov/show/NCT01590121 Completed Imperial College London 2011-10-31
NCT01354093 The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel) https://ClinicalTrials.gov/show/NCT01354093 Completed University of Utah 2017-01-31
NCT04037189 Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia https://ClinicalTrials.gov/show/NCT04037189 Recruiting Rabin Medical Center 2021-07-28
NCT03942315 Recurrence of Hereditary Hemorrhagic Telangiectasia (HHT) After Liver Transplantation https://ClinicalTrials.gov/show/NCT03942315 Completed Hospices Civils de Lyon 2018-02-01
NCT03940014 Pulmonary Arteriovenous Malformations (PAVMs) in Hereditary Haemorrhagic Telangiectasia (HHT) https://ClinicalTrials.gov/show/NCT03940014 Completed Hospices Civils de Lyon 2017-03-01
NCT03841422 Evaluation of Video-assisted Instructions of Nasal Self-packing in Patients With HHT https://ClinicalTrials.gov/show/NCT03841422 Recruiting University Hospital, Essen 2020-12-31
NCT03691142 Evaluation of Obstetrical and Neonatal Complications in Hereditary Haemorrhagic Telangiectasia (HHT) https://ClinicalTrials.gov/show/NCT03691142 Completed Hospices Civils de Lyon 2019-10-02
NCT03572556 Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT) https://ClinicalTrials.gov/show/NCT03572556 Recruiting Centre Hospitalier Universitaire Dijon 2020-12-31
NCT03549949 Nationwide Awareness Campaign and Call for Dental Screening for HHT in Germany https://ClinicalTrials.gov/show/NCT03549949 Recruiting University Hospital, Essen 2020-06-30
NCT00733655 Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia https://ClinicalTrials.gov/show/NCT00733655 Active, not recruiting Imperial College London 2020-08-31
NCT00684879 Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia https://ClinicalTrials.gov/show/NCT00684879 Completed National Institutes of Health Clinical Center (CC) NA
NCT01158807 Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia https://ClinicalTrials.gov/show/NCT01158807 Recruiting St. Michael’s Hospital, Toronto 2024-09-30
NCT00230659 Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia https://ClinicalTrials.gov/show/NCT00230659 Completed Imperial College London 2007-07-31
NCT00230633 Studies of White Blood Cells Derived From HHT Patients https://ClinicalTrials.gov/show/NCT00230633 Active, not recruiting Imperial College London 2026-10-31
NCT00230620 Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families https://ClinicalTrials.gov/show/NCT00230620 Recruiting Imperial College London 2018-11-30
NCT00005392 Epidemiology of Venous Disease https://ClinicalTrials.gov/show/NCT00005392 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005386 Biobehavioral Determinants of Obesity in Black Women https://ClinicalTrials.gov/show/NCT00005386 Completed University of Memphis NA
NCT00004649 Study of the Natural History and Genotype-Phenotype Correlations of Hereditary Hemorrhagic Telangiectasia Patients https://ClinicalTrials.gov/show/NCT00004649 Completed Office of Rare Diseases (ORD) NA
NCT00004648 Studies of Hereditary Hemorrhagic Telangiectasia https://ClinicalTrials.gov/show/NCT00004648 Completed Office of Rare Diseases (ORD) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT01793168 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford https://ClinicalTrials.gov/show/NCT01793168 Recruiting Sanford Health 2100-12-31
NCT04150822 Hereditary Hemorrhagic Telangiectasia (HHT) Research Outcomes Registry https://ClinicalTrials.gov/show/NCT04150822 Recruiting St. Michael’s Hospital, Toronto 2028-12-31